For details please refer to the section Investors/Financial Statements, Reports and Presentations


GUIDANCE

Note: The Guidance FY 2023 envisages the full consolidation of Blampin and Capexo as from Jan.1,2023. % chg. are calculated on median values.

(*) Excluding possible LTI/MBO to mature in 2022 and 2023 but including annual accruals of LTI matured in 2020 and 2021 .

(**) Excluding the increase in fixed assets due to the application of IFRS 16 but including ESG related investments.

 


FINANCIAL HIGHLIGHTS

 

Thousand of euro 31.12.2021 31.12.2020 31.12.2019
Net sales 1.069.776 1.041.535 1.005.718
Adjusted Ebitda* 52.929 48.404 38.706
% Adjusted Ebitda 4,9% 4,6% 3,8%
Adjusted Ebit 25.526 22.414 12.953
Ebit 23.135 18.763 8.378
Profit/loss 18.508 12.269 2.264
Adjusted profit/loss 19.093 13.979 5.280
* Adjusted Ebitda: it’s determined by adding to the Operating Result (EBIT) the amounts for depreciation, amortization, and provisions, and excluding non-recurring costs/income and costs related to the Top management incentives

 

Thousand of euro 31.12.2021 31.12.2020 31.12.2019
Net Invested Capital 260.199 263.423 277.830
Total Shareholders’ Equity 175.186 160.111 150.931
Net Financial Position 84.346 103.311 126.898
Financial Ratios:
Net Financial Position/Total Shareholders’ Equity 0,48 0,65 0,84
Net Financial Position/Adjusted Ebitda 1,59 2,13 3,28